Market Pulse Breaking News Alert for Monday, December 14, 2009: RMCP - RevMed Launches RevVac Safety Syringe Mass Manufacturing
December 14 2009 - 7:30AM
Marketwired
Market Pulse News Alert for this AM, Stocks to Watch are:
Revolutions Medical Corporation (OTCBB: RMCP), Sunesis
Pharmaceuticals Inc. (NASDAQ: SNSS), Blue Gem Enterprise (OTCBB:
BGEM) and Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC).
Investors need to be watching Revolutions Medical Corporation
(OTCBB: RMCP) this AM! Revolutions Medical Corporation (RevMed) is
engaged in the design, development, commercialization and
acquisition of new products and tools to make healthcare safer and
less expensive. RevMed's products include safety-engineered medical
devices (SEMDs) and the flagship RevVac safety syringe (FDA
Approved), safety blood drawing devices, and safety IV catheters.
The products use a proprietary patented technology in which a
vacuum causes the needle to retract into the barrel of the syringe
or device after an injection is administered or blood is drawn.
RevMed owns the patents to manufacture the disposable retractable
syringe and phlebotomy device. The world market for SEMDs is
projected to exceed $2 billion this year and is forecasted to
maintain a 20% annual growth rate in the near term. RevMed also
offers RevColor, RevDisplay and Rev3D software solutions and
proprietary tools that are compatible with standard MRIs and
standard PACS. The software includes sorting of images, color, 3D,
and automatic segmentation of images. These tools will enhance the
physician's diagnostic confidence in an industry that is growing at
10% - 15% (more than 25 million procedures) per year with a
worldwide market potential for these tools that exceeds $3.5
billion. The company is continually looking for new and improved
technology through internal product development and acquisition.
The company's future growth will be powered by new product line
introductions, and the material expansion of existing successful
lines. RevMed's Breast Biopsy System (BBS), stereotactic (minimally
invasive) image-based localization technology, is one of those
product lines pursuing the $9.5 billion breast screening industry.
RevMed's Breast Biopsy System, the MRI enhancement software and the
SEMDs will be launching in the next 18 months. All three markets
are immediately addressable and total more than $14 billion. RevMed
recently introduced its proprietary suite of MRI software products
at the Radiology Society of North America annual meeting with great
success. Radiologists and universities world-wide received
presentations at the RMCP booth. A number of these contacts could
play an important role in the company's ongoing efforts to
clinically validate specific applications of its MRI tools prior to
the 2010 commercial launch. Never has health care been a hotter
issue, and the focus of the conversation is on increased safety at
dramatically reduced cost. Revolutions Medical has the formula for
success, and one that has them immediately positioned for a high
growth future. With 3 recurring revenue business lines with blended
gross margins projected to exceed 50% and anticipated profitability
in its first full year of operations, Revolutions Medical
Corporation is poised to become a significant player in the
healthcare and medical devices industry! RMCP has had several
excellent press releases out lately and one again before today's
opening bell announcing that it has initiated the mass
manufacturing process for the RevVac safety syringe, which is
already FDA approved! The company also said it's on pace to meet
its Q2 '10 sales launch goal and $14.8 million 2010 revenue
projection! This could be great news for investors!
Revolutions Medical Corporation (OTCBB: RMCP), producers of the
RevVac safety syringe, RevColor, RevDisplay and Rev3D MRI
Technology, today announced that it has initiated the mass
manufacturing process for the RevVac safety syringe, which is
already FDA approved. By hitting its primary milestone, RevMed
satisfies its previously announced commitment to begin production
in Q4 '09. It also stays on pace to meet its Q2 '10 sales launch
goal and $14.8 million 2010 revenue projection.
"After years in developing what we believe is the world's best
safety syringe, we are extremely pleased to announce that the plan
is now reality -- we have launched the mass manufacturing process
for the RevVac safety syringe," stated Revolutions Medical CTO
Richard Theriault. "This constitutes the next step toward full
scale high volume production and commercialization. With this first
phase we will 1) provide market-ready samples and 2) complete the
steps necessary to ensure ultimate delivery of a high quality, high
volume manufacturing solution. We have been working closely with
the team at Goddard Technologies (www.goddardtech.com) -- the group
responsible for the recent crucial product refinements -- towards
this, our primary pre-sales milestone. We remain precisely on pace
with our stated goals, and we can now demonstrate tangible progress
toward bringing the much-anticipated RevVac to market in Q2
'10."
Andrew Goddard, President of Goddard Technologies, stated, "We
are pleased to be working with Revolutions Medical on the first
phase of the RevVac Safety Syringe mass manufacturing process. The
RevVac design is unique and elegant as an easy to use, single
handed vacuum safety syringe. That we could contribute to a product
of such high caliber is a source of great pride for Goddard
Technologies."
About Revolutions Medical Corporation
(www.revolutionsmedical.com)
RevMed's products include the RevVac safety syringe (FDA
approved), safety blood drawing device and safety IV catheter.
RevMed also provides RevColor, RevDisplay and Rev3D -- software
solutions and proprietary tools that are compatible with standard
MRIs and standard PACS. The software suite's functionality includes
sorting of images, color, 3D and automatic segmentation of
images.
Stocks in the news, and acting well as of late, include: Sunesis
Pharmaceuticals Inc. (NASDAQ: SNSS), Blue Gem Enterprise (OTCBB:
BGEM) and Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC).
Information contained herein is the opinion of Market-Pulse.com
("MP") and is intended to be used strictly for informational
purposes. You should be aware that MP attempts to assure itself of
the accuracy of the information contained in the analyses it
publishes. In this regard, MP does, at times, rely on the accuracy
of information supplied to it by the companies which are the
subject of MP's analyses and/or parties related to those companies.
MP also relies on the accuracy and integrity of information that is
contained in company press releases and reports filed with the SEC.
The companies mentioned in this publication have not approved the
content or timing of the information being published unless
otherwise noted.
MP, because it relies on information supplied by various third
parties disclaims any responsibility for the accuracy of such
information. Any investor considering making an investment in any
security which has been the subject of a MP analysis or opinion
should, before making any such investment, consult with his/her
market professional and/or do his/her own independent research
regarding the company which is the subject of an MP opinion,
recommendation or analysis. Information regarding companies which
MP has opined upon is normally available from many sources
including the subject company's filings with the SEC and various
press releases issued by the company.
You should be aware that MP is often compensated for issuing
analyses, recommendations or opinions concerning particular
companies. Its opinion is therefore not unbiased and you should
consider this factor when evaluating MP's statements regarding a
company. MP has been compensated twenty five thousand restricted
shares of Revolutions Medical Corporation by the company. MP's
officers and directors reserve the right to buy additional shares
of the companies discussed in this opinion and may profit in the
event those shares rise in value. When MP receives shares as
compensation for a profiled company, MP may sell part or all of any
such shares during the period in which MP is performing such
services. Market-Pulse.com and Market Pulse Breaking News Alert are
owned by Market Pulse LLC.
Contact: Market Pulse 800.290.8935 Email Contact
Blue Gem Enterprise (CE) (USOTC:BGEM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Blue Gem Enterprise (CE) (USOTC:BGEM)
Historical Stock Chart
From Sep 2023 to Sep 2024